<DOC>
	<DOCNO>NCT00811486</DOCNO>
	<brief_summary>Secondary hyperaldosteronism non-osmotic release arginine vasopressin ( AVP ) major factor sodium water retention pulmonary arterial hypertension right ventricular failure . Natriuretic dos mineralocorticoid antagonist aquaretic dos V2 receptor antagonist attenuate sodium water retention respectively , associated clinical improvement .</brief_summary>
	<brief_title>Body Volume Regulation Pulmonary Arterial Hypertension With Right Ventricular Failure</brief_title>
	<detailed_description>Much learn pathophysiological state underlies development increase total body volume edema leave ventricular failure . Very little , however , know mechanism underlie systemic hypervolemia patient isolate right ventricular dysfunction . Patients pulmonary arterial hypertension ( PAH ) represent model isolate right ventricular dysfunction mechanism may elucidate . Aldosterone show many property likely detrimental congestive heart failure ( CHF ) share angiotensin II . Aldosterone blockade associate improved mortality patient leave ventricular failure , already receive angiotensin convert enzyme inhibitor . But role isolate right ventricular failure elucidate . The plasma arginine vasopressin level disproportionately elevate degree serum osmolarity patient heart failure result water retention hyponatremia . Conivaptan , vasopressin receptor antagonist , appear reduce body weight improve sign leave heart failure , though study evaluate role right ventricular failure edema . This study examine role spironolactone conivaptan patient right ventricular failure pathophysiology sodium water retention patient .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Conivaptan</mesh_term>
	<criteria>1 . Patients World Health Organization ( WHO ) group 1 pulmonary arterial hypertension [ 51 ] , exclude patient portal hypertension , meet follow hemodynamic parameter : Mean pulmonary artery pressure ( mPAP ) &gt; 35 mmHg rest , Pulmonary capillary wedge pressure ( PCWP ) &lt; 15 mmHg , Pulmonary vascular resistance ( PVR ) &gt; 1.5 wood unit , 2 . Age 18 75 year 3 . Right ventricular failure define right atrial pressure &gt; 7 mmHg along either dilate right ventricle , absence inferior vena cava collapse BNP &gt; 100 pg/ml 4 . Patients childbearing age must practice effective birth control . 5 . Normal leave ventricular function assess echocardiogram , multiple gated acquisition ( MUGA ) cardiac scan , invasive leave ventriculography . 1 . Group 25 pulmonary hypertension define WHO . Pulmonary hypertension leave heart failure ( assessed echocardiogram , multiple gated acquisition ( MUGA ) cardiac scan , invasive leave ventriculography ) . Pulmonary hypertension associate lung disease and/or hypoxemia ( e.g . chronic obstructive pulmonary disease , interstitial lung disease , sleep disorder breathing , chronic exposure high altitude , alveolar hypoventilation syndrome . Pulmonary hypertension due chronic thrombotic and/or embolic diseases Miscellaneous sarcoidosis , compression pulmonary vessel adenopathy , tumor 2 . Systemic hypertension , define systolic pressure &gt; 140 mmHg diastolic blood pressure &gt; 90 mmHg 3 . Patients take angiotensin convert enzyme ( ACE ) inhibitor angiotensin receptor blocker ( ARBs ) 4 . Pregnancy 5 . Chronic kidney disease ( serum creatinine &gt; 2.5mg/dl , proteinuria &gt; 500 mg/day , hematuria ) 6 . Cirrhosis portal hypertension 7 . Inability provide inform consent . 8 . Allergy conivaptan spironolactone . 9 . Active malignancy 10 . Patients receive spironolactone 11 . Enrollment interventional study . 12 . Patients Highly Active Antiretroviral Therapy ( HAART )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>